Interview
23andMe ft. Anne Wojcicki - How a DNA startup took on the FDA and redefined health tech
- The company plans to evolve its business model from data provision to a "full stack" approach offering subscription products and telehealth services, utilizing the acquisition of Lemonade Health to provide clinicians and a pharmacy across all 50 states.
- The organization aims to become the world's leader in genomic-based medicine by leveraging a database expected to eventually reach 10 million people, currently holding 12 to 14 million, to drive personalized prevention strategies and medication selection based on genetic components.
- Therapeutics development includes an investigational cancer drug (23andMe 610) currently in phase two testing, with a biochemical molecular biology lab built from scratch using acquired equipment and talent, targeting antibody therapeutics based on over 50 identified programs in collaboration with GSK and other pharma partners.
- Future drug authorization faces significant regulatory hurdles, including a requirement for two years of meticulous testing and data provision to the FDA, a process described as slow, painful, and capable of taking years to complete.
- Market expectations include over 90% of physicians eventually understanding the clinical benefits of genetics, with the brand aiming to become "contagious" through persistence, data, and activism rather than immediate breakthroughs.
- The company anticipates challenges related to scaling, such as increasing difficulty in execution, the need to inspire risk-taking leadership, and overcoming perceptions of being a traditional direct-to-consumer ancestry company rather than a therapeutics innovator.
- Strategic pivots involved addressing past sales flatlining and regulatory crises, including a 2013 FDA warning that forced the cessation of health testing services and a subsequent hiring of a chief legal and regulatory officer with over two decades of experience.
- Operational adjustments included layoffs of roughly 100 employees (14% of the workforce), reallocation of marketing budgets to reignite growth, and a decision to build an in-house genomics expertise division due to a lack of such capability within traditional pharma companies.
- Historical risks included consumer privacy concerns exacerbated by the Cambridge Analytica and Golden State Killer incidents, which necessitated transparent communication about data usage to maintain trust and demonstrate accuracy.
- Long-term success depends on the company's ability to navigate the transition from an unregulated to a regulated entity, maintain an "incredibly dedicated" therapeutics team, and prove that genomic foundations make drugs two to three times more likely to succeed.